[Pituitary adenylate-cyclase activating polypeptide (PACAP)-targeting treatment as a potential migraine prophylactic therapy].

In migraine prevention, new treatments are being explored that target PACAP. Current options include monoclonal antibodies (mAbs) and other specific drugs. Researchers conducted a review of existing literature on this topic. They also completed a Phase 2a clinical trial with a mAb targeting the PAC1 receptor. Unfortunately, results showed no significant difference in migraine reduction compared to placebo. Another study, the HOPE study, tested a different mAb, Lu AG09222, on patients with episodic and chronic migraines. This study used both low and high doses of the drug. After four weeks, patients receiving the high dose experienced a reduction of -6.2 migraine days per month. In contrast, those receiving a placebo had a reduction of -4.2 days. These findings suggest that while PACAP-targeting treatments may show promise, more research is needed to confirm their effectiveness. Clinical relevance: This research indicates that targeting PACAP may help some migraine patients, but further studies are necessary to establish its effectiveness compared to existing treatments.